Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 3.51 USD 4.78%
Market Cap: 1.1B USD

Intrinsic Value

The intrinsic value of one ABCL stock under the Base Case scenario is 0.76 USD. Compared to the current market price of 3.51 USD, Abcellera Biologics Inc is Overvalued by 78%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ABCL Intrinsic Value
0.76 USD
Overvaluation 78%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Abcellera Biologics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about ABCL?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ABCL valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Abcellera Biologics Inc.

Explain Valuation
Compare ABCL to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ABCL?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Abcellera Biologics Inc

Current Assets 695.1m
Cash & Short-Term Investments 495.7m
Receivables 159.4m
Other Current Assets 40.1m
Non-Current Assets 660.9m
Long-Term Investments 93.3m
PP&E 427.4m
Intangibles 87.1m
Other Non-Current Assets 53.1m
Current Liabilities 68.8m
Accounts Payable 31.8m
Accrued Liabilities 12.4m
Other Current Liabilities 24.6m
Non-Current Liabilities 323.2m
Other Non-Current Liabilities 323.2m
Efficiency

Free Cash Flow Analysis
Abcellera Biologics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Abcellera Biologics Inc

Revenue
35.3m USD
Operating Expenses
-296.6m USD
Operating Income
-261.3m USD
Other Expenses
89.6m USD
Net Income
-171.7m USD
Fundamental Scores

ABCL Profitability Score
Profitability Due Diligence

Abcellera Biologics Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Declining Net Margin
Low Gross Margin
Declining Operating Margin
14/100
Profitability
Score

Abcellera Biologics Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

ABCL Solvency Score
Solvency Due Diligence

Abcellera Biologics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
66/100
Solvency
Score

Abcellera Biologics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABCL Price Targets Summary
Abcellera Biologics Inc

Wall Street analysts forecast ABCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABCL is 10.03 USD with a low forecast of 7.07 USD and a high forecast of 16.8 USD.

Lowest
Price Target
7.07 USD
101% Upside
Average
Price Target
10.03 USD
186% Upside
Highest
Price Target
16.8 USD
379% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Abcellera Biologics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ABCL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ABCL Insider Trading
Buy and sell transactions by insiders

ABCL News

Other Videos
What is the Intrinsic Value of one ABCL stock?

The intrinsic value of one ABCL stock under the Base Case scenario is 0.76 USD.

Is ABCL stock undervalued or overvalued?

Compared to the current market price of 3.51 USD, Abcellera Biologics Inc is Overvalued by 78%.

Back to Top